Janux Therapeutics, Inc.

NASDAQ (USD): Janux Therapeutics, Inc. (JANX)

Last Price

59.86

Today's Change

+19.68 (48.97%)

Day's Change

59.30 - 71.25

Trading Volume

7,658,646

Overview

Market Cap

3 Billion

Shares Outstanding

52 Million

Avg Volume

692,417

Avg Price (50 Days)

49.68

Avg Price (200 Days)

44.82

PE Ratio

-51.16

EPS

-1.17

Earnings Announcement

07-Mar-2025

Previous Close

40.18

Open

67.00

Day's Range

59.3043 - 71.25

Year Range

7.79 - 71.25

Trading Volume

7,658,646

Price Change Highlight

1 Day Change

48.98%

5 Day Change

29.76%

1 Month Change

7.14%

3 Month Change

34.61%

6 Month Change

23.37%

Ytd Change

443.19%

1 Year Change

549.24%

3 Year Change

254.20%

5 Year Change

138.01%

10 Year Change

138.01%

Max Change

138.01%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment